Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide

Transfusion

Volumn 54, Issue 10, 2014, Pages 2514-2522

  Morris, Curly ^a   De Wreede, Liesbeth ^b   Scholten, Marijke ^b   Brand, Ronald ^b   Van Biezen, Anja ^b   Sureda, Anna ^c   Dickmeiss, Ebbe ^d   Trneny, Marek ^e   Apperley, Jane ^f   Chiusolo, Patrizia ^g   Van Imhoff, Gustaaf W ^h   Lenhoff, Stig ⁱ   Martinelli, Giovanni ^j   Hentrich, Marcus ^k   Pabst, Thomas ^l   Onida, Francesco ^m   Quinn, Michael ⁿ   Kroger, Nicolaus ^o   De Witte, Theo ^p   Ruutu, Tapani ^q  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e CHARLES UNIVERSITY   (Czech Republic)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k Klinikum Harlaching   (Germany)

^l UNIVERSITY OF BERN   (Switzerland)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ BELFAST CITY HOSPITAL   (United Kingdom)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^q HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; DIMETHYL SULFOXIDE; ETOPOSIDE; MELPHALAN; CRYOPROTECTIVE AGENT;

ABDOMINAL DISEASE; ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; LUNG DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; NAUSEA; NEUROLOGICAL COMPLICATION; PROSPECTIVE STUDY; VOMITING; ADOLESCENT; AUTOTRANSPLANTATION; BLOOD STORAGE; BONE MARROW CELL; CRYOPRESERVATION; DOSE RESPONSE; EUROPE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; OSMOLARITY; PROCEDURES; STANDARDS; TRANSFUSION REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD PRESERVATION; BONE MARROW CELLS; CRYOPRESERVATION; CRYOPROTECTIVE AGENTS; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; TRANSFUSION REACTION; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84908101326     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12759     Document Type: Article

References (44)

1. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485-501.
2. Piatkowska-Jakubas B, Wolska-Smolen T, Mensah-Glanowska P, et al. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients-single centre experience. Przegl Lek 2011; 68: 78-81.
3. Ferrara F, Izzo T, Criscuola C, et al. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol 2011; 29: 139-143.
4. O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731-737.
5. Nivison-Smith I, Bradstock KF, Dodds AJ, et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905-912.
6. Cordoba R, Arrieta R, Kerguelen A, et al. The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product. Bone Marrow Transplant 2007; 40: 1063-1067.
7. Bojac I, Cepulic BG, Mazic S, et al. Toxicity related to autologous peripheral blood haematopoietic progenitor cell infusion is associated with number of granulocytes in graft, gender and diagnosis of multiple myeloma. Vox Sang. 2008; 95: 70-75.
8. Marin-Henao GA, Resano PM, Villegas JMS, et al. Adverse reactions during transfusion of thawed haematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis product. Vox Sang 2010; 99: 267-273.
9. Santos NC, Figueira-Coelho J, Martins-Silva J, et al. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003; 65: 1035-1041.
10. Davis JM, Rowley SD, Braine HG, et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781-786.
11. Alessandrino EP, Bernasconi P, Caldera D, et al. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Bone Marrow Transplant 1999; 23: 533-537.
12. Zambelli A, Poggi G, Da Prada G, et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998; 18: 4705-4708.
13. Zenhausern R, Tobles A, Leoncini L, et al. Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann Hematol 2000; 79: 523-526.
14. Benekli M, Anderson B, Wentling D, et al. Severe respiratory depression after dimethyl sulfoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transplant 2000; 25: 1299-1301.
15. Miniero R, Vai S, Giacchino M, et al. Severe respiratory depression after autologous bone marrow infusion. Haematologica 1992; 77: 98-99.
16. Corso S, Vukelja SJ, Wiender D, et al. Diffuse alveolar hemorrhage following autologous bone marrow infusion. Bone Marrow Transplant 1993; 12: 301-303.
17. Higman MA, Port JD, Beauchamp NJ Jr, et al. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplant 2000; 26: 797-800.
18. Ferrucci PF, Marinoni A, Cocoroccchio E, et al. Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant 2000; 25: 173-177.
19. Gomez S, Nagler A, Naparstek E, et al. Transient elevation of serum lactic dehydrogenase following autologous bone marrow transplantation. Bone Marrow Transplant 1991; 7: 487-488.
20. Burger J, Gilmore MJ, Jackson B, et al. Acute haemoglobinaemia associated with the reinfusion of bone marrow buffy coat for autologous bone marrow transplantation. Bone Marrow Transplant 1991; 7: 322-324.
21. Joint UK Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. Guidelines for the Blood Transfusion Services in the UK (The Red Book). 8th ed. Section 22.10. 2013. [cited 2014 Jun 13]. Available from: http://www.transfusionguidelines.org.uk
22. Rowley SD, Bensinger WI, Gooley TA, et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731-2736.
23. Windrum P, Morris TC, Drake MB, et al. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant 2005; 36: 601-603.
24. Galmes A, Gutlerrez A, Sampol A, et al. Long-term hematologic reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at -80°C in a mechanical freezer. Haematologica 2007; 92: 986-989.
25. Galmes A, Besalduch J, Bargay J, et al. Cryopreservation of hematopoietic progenitor cells with 5-percent dimethyl sulfoxide at -80 degrees C without rate-controlled freezing. Transfusion 1996; 36: 794-797.
26. Rowley SD, Feng Z, Chen L, et al. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydoryethylstarch. Bone Marrow Transplant 2003; 31: 1043-1051.
27. Halle P, Tourmilhac O, Knopinska-Posluszny W, et al. Uncontrolled-rate freezing and storage at -80 degrees C, with only 3.5 percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations. Transfusion 2001; 41: 667-673.
28. Beaujean F, Bourhis J-H, Bayle C, et al. Successful cryopreservation of purified autologous CD34+ cells: influence of freezing parameters on cell recovery and engraftment. Bone Marrow Transplant 1998; 22: 1091-1096.
29. Lemarie C, Calmels B, Malenfant C, et al. Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: cytoMate. Transfusion 2005; 45: 737-742.
30. Rowley SD, Feng Z, Yadock D, et al. Post-thaw removal of DMSO does not completely abrogate infusional toxicity or the need for pre-infusion histamine blockade. Cytotherapy 1999; 1: 439-446.
31. Akkok CA, Holte MR, Tangen JM, et al. Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells. Transfusion 2009; 49: 354-361.
32. Syme R, Bewick M, Stewart D, et al. The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004; 10: 135-141.
33. Calmels B, Lemarie C, Esterni B, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion 2007; 47: 1268-1275.
34. TM, for washing out DMSO from hematopoietic stem cell grafts after thawing. Bone Marrow Transplant 2003; 31: 823-828.
35. Martino M, Morabito F, Messina G, et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 1996; 81: 59-61.
36. Liseth K, Ersvoer E, Abrahamsen JF, et al. Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells. Transfusion 2009; 49: 1709-1719.
37. Akalin CA, Liseth K, Hervig T, et al. Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts soluble mediators. Cytotherapy 2009; 11: 749-760.
38. Lakota J, Fuchsberger P,. Autologous stem cell transplantation with stem cells preserved in the presence of 4.5 and 2.2% DMSO. Bone Marrow Transplant 1996; 18: 262-263.
39. Halle P, Tournilhac O, Knopinska-Posluszny W, et al. Uncontrolled-rate freezing and storage at -80°C, with only 3.5-percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations. Transfusion 2011; 41: 667-673.
40. Galmes A, Besalduch J, Bargay J, et al. Long-term storage at -80°C of hematopoietic progenitor cells with 5-percent dimethyl sulfoxide as the sole cryoprotectant. Transfusion 1999; 39: 70-73.
41. Bakken AM, Bruserud O, Abrahamsen JF,. No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide. J Hematother Stem Cell Res 2003; 12: 351-358.
42. Veeraputhiran M, Theus JW, Pesek G, et al. Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage of dimethyl sulfoxide concentration. Cytotherapy 2010; 12: 764-766.
43. Akkok CA, Liseth K, Nesthus I, et al. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation. Transfusion 2008; 48: 877-883.
44. Galmes A, Gutierrez A, Sampol A, et al. Long-term haematological reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at -80 degrees C in a mechanical freezer. Haematologica 2007; 92: 986-989.